158 related articles for article (PubMed ID: 37316799)
1. The Rac inhibitor HV-107 as a potential therapeutic for metastatic breast cancer.
Crespo GV; Ortiz J; O'Farrill EH; Vlaar CP; Inyushin M; Kucheryavykh Y; Kucheryavykh L
Mol Med; 2023 Jun; 29(1):75. PubMed ID: 37316799
[TBL] [Abstract][Full Text] [Related]
2. Rac and Cdc42 inhibitors reduce macrophage function in breast cancer preclinical models.
Torres-Sanchez A; Rivera-Robles M; Castillo-Pichardo L; Martínez-Ferrer M; Dorta-Estremera SM; Dharmawardhane S
Front Oncol; 2023; 13():1152458. PubMed ID: 37397366
[TBL] [Abstract][Full Text] [Related]
3. Characterization of EHop-016, novel small molecule inhibitor of Rac GTPase.
Montalvo-Ortiz BL; Castillo-Pichardo L; Hernández E; Humphries-Bickley T; De la Mota-Peynado A; Cubano LA; Vlaar CP; Dharmawardhane S
J Biol Chem; 2012 Apr; 287(16):13228-38. PubMed ID: 22383527
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of Rac and Cdc42 Inhibitor MBQ-167 in Triple-negative Breast Cancer.
Cruz-Collazo A; Ruiz-Calderon JF; Picon H; Borrero-Garcia LD; Lopez I; Castillo-Pichardo L; Del Mar Maldonado M; Duconge J; Medina JI; Bayro MJ; Hernández-O'Farrill E; Vlaar CP; Dharmawardhane S
Mol Cancer Ther; 2021 Dec; 20(12):2420-2432. PubMed ID: 34607932
[TBL] [Abstract][Full Text] [Related]
5. Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer.
Lee J; Lim B; Pearson T; Choi K; Fuson JA; Bartholomeusz C; Paradiso LJ; Myers T; Tripathy D; Ueno NT
Breast Cancer Res Treat; 2019 Jun; 175(2):339-351. PubMed ID: 30826934
[TBL] [Abstract][Full Text] [Related]
6. XS-2, a novel potent dual PI3K/mTOR inhibitor, exhibits high in vitro and in vivo anti-breast cancer activity and low toxicity with the potential to inhibit the invasion and migration of triple-negative breast cancer.
Xu S; Sun X; Luo L; Yang Y; Guo Q; Tang S; Jiang Z; Li Y; Han J; Gan W; Yang F; Zhang X; Liu Y; Sun C; He J; Liu M; Zuo D; Zhu W; Wu Y
Biomed Pharmacother; 2022 Nov; 155():113537. PubMed ID: 36113258
[TBL] [Abstract][Full Text] [Related]
7. Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation.
Andey T; Sudhakar G; Marepally S; Patel A; Banerjee R; Singh M
Mol Pharm; 2015 Apr; 12(4):1105-20. PubMed ID: 25661724
[TBL] [Abstract][Full Text] [Related]
8. Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat.
Tate CR; Rhodes LV; Segar HC; Driver JL; Pounder FN; Burow ME; Collins-Burow BM
Breast Cancer Res; 2012 May; 14(3):R79. PubMed ID: 22613095
[TBL] [Abstract][Full Text] [Related]
9. Rubioncolin C, a natural naphthohydroquinone dimer isolated from Rubia yunnanensis, inhibits the proliferation and metastasis by inducing ROS-mediated apoptotic and autophagic cell death in triple-negative breast cancer cells.
Li L; Wang J; Feng L; Fan J; Wang J; Tan N; Wang Z
J Ethnopharmacol; 2021 Sep; 277():114184. PubMed ID: 33961996
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous blockade of IL-6 and CCL5 signaling for synergistic inhibition of triple-negative breast cancer growth and metastasis.
Jin K; Pandey NB; Popel AS
Breast Cancer Res; 2018 Jun; 20(1):54. PubMed ID: 29898755
[TBL] [Abstract][Full Text] [Related]
11. Rhizoma Amorphophalli inhibits TNBC cell proliferation, migration, invasion and metastasis through the PI3K/Akt/mTOR pathway.
Wu C; Qiu S; Liu P; Ge Y; Gao X
J Ethnopharmacol; 2018 Jan; 211():89-100. PubMed ID: 28962890
[TBL] [Abstract][Full Text] [Related]
12. Characterization of Novel Derivatives of MBQ-167, an inhibitor of the GTP-binding proteins Rac/Cdc42.
Medina JI; Cruz-Collazo A; Del Mar Maldonado M; Gascot TM; Borrero-Garcia LD; Cooke M; Kazanietz MG; O'Farril EH; Vlaar CP; Dharmawardhane S
Cancer Res Commun; 2022 Dec; 2(12):1711-1726. PubMed ID: 36861094
[TBL] [Abstract][Full Text] [Related]
13. The Rac Inhibitor EHop-016 Inhibits Mammary Tumor Growth and Metastasis in a Nude Mouse Model.
Castillo-Pichardo L; Humphries-Bickley T; De La Parra C; Forestier-Roman I; Martinez-Ferrer M; Hernandez E; Vlaar C; Ferrer-Acosta Y; Washington AV; Cubano LA; Rodriguez-Orengo J; Dharmawardhane S
Transl Oncol; 2014 Oct; 7(5):546-55. PubMed ID: 25389450
[TBL] [Abstract][Full Text] [Related]
14. Development of EHop-016: a small molecule inhibitor of Rac.
Dharmawardhane S; Hernandez E; Vlaar C
Enzymes; 2013; 33 Pt A(Pt A):117-46. PubMed ID: 25033803
[TBL] [Abstract][Full Text] [Related]
15. Two distinct mTORC2-dependent pathways converge on Rac1 to drive breast cancer metastasis.
Morrison Joly M; Williams MM; Hicks DJ; Jones B; Sanchez V; Young CD; Sarbassov DD; Muller WJ; Brantley-Sieders D; Cook RS
Breast Cancer Res; 2017 Jun; 19(1):74. PubMed ID: 28666462
[TBL] [Abstract][Full Text] [Related]
16. Characterization of a Dual Rac/Cdc42 Inhibitor MBQ-167 in Metastatic Cancer.
Humphries-Bickley T; Castillo-Pichardo L; Hernandez-O'Farrill E; Borrero-Garcia LD; Forestier-Roman I; Gerena Y; Blanco M; Rivera-Robles MJ; Rodriguez-Medina JR; Cubano LA; Vlaar CP; Dharmawardhane S
Mol Cancer Ther; 2017 May; 16(5):805-818. PubMed ID: 28450422
[TBL] [Abstract][Full Text] [Related]
17. FGF13 promotes metastasis of triple-negative breast cancer.
Johnstone CN; Pattison AD; Harrison PF; Powell DR; Lock P; Ernst M; Anderson RL; Beilharz TH
Int J Cancer; 2020 Jul; 147(1):230-243. PubMed ID: 31957002
[TBL] [Abstract][Full Text] [Related]
18. A triple combination gemcitabine + romidepsin + cisplatin to effectively control triple-negative breast cancer tumor development, recurrence, and metastasis.
Pattarawat P; Hunt JT; Poloway J; Archibald CJ; Wang HR
Cancer Chemother Pharmacol; 2021 Sep; 88(3):415-425. PubMed ID: 34043046
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and validation of novel nitrogen-based chalcone analogs against triple negative breast cancer.
Elkhalifa D; Siddique AB; Qusa M; Cyprian FS; El Sayed K; Alali F; Al Moustafa AE; Khalil A
Eur J Med Chem; 2020 Feb; 187():111954. PubMed ID: 31838326
[TBL] [Abstract][Full Text] [Related]
20. The small G-protein RalA promotes progression and metastasis of triple-negative breast cancer.
Thies KA; Cole MW; Schafer RE; Spehar JM; Richardson DS; Steck SA; Das M; Lian AW; Ray A; Shakya R; Knoblaugh SE; Timmers CD; Ostrowski MC; Chakravarti A; Sizemore GM; Sizemore ST
Breast Cancer Res; 2021 Jun; 23(1):65. PubMed ID: 34118960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
